Anabolic Agents and the Bone Morphogenetic Protein Pathway

Current Topics in Developmental Biology

Volumn 78, Issue , 2007, Pages 127-171

  Garrett, I R ^a  

^a OsteoScreen   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; BONE MORPHOGENETIC PROTEIN;

ANIMAL; DRUG EFFECT; HUMAN; OSTEOPOROSIS; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANABOLIC AGENTS; ANIMALS; BONE MORPHOGENETIC PROTEINS; HUMANS; OSTEOPOROSIS; SIGNAL TRANSDUCTION;

EID: 33847292822     PISSN: 00702153     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0070-2153(06)78004-8     Document Type: Review

References (312)

1. Aberle H., Bauer A., Stappert J., Kispert A., and Kemler R. Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 16 (1997) 3797-3804
2. Acologix R. Acologix web site - 4-10-06 (2006)
3. Agnusdei D., Zacchei F., Bigazzi S., Cepollaro C., Nardi P., Montagnani M., and Gennari C. Metabolic and clinical effects of ipriflavone in established post-menopausal osteoporosis. Drugs Exp. Clin. Res. 15 (1989) 97-104
4. Akamine T., Jee W.S., Ke H.Z., Li X.J., and Lin B.Y. Prostaglandin E2 prevents bone loss and adds extra bone to immobilized distal femoral metaphysis in female rats. Bone 13 (1992) 11-22
5. Akin S., Korkusuz F., Ungan M., and Enköylü A. Bone mineral density of lumbar spine and proximal femur in healthy males. J. Radioanal. Nucl. Chem. 259 (2004) 361-364
6. Alexandersen P., Toussaint A., Christiansen C., Devogelaer J.P., Roux C., Fechtenbaum J., Gennari C., and Reginster J.Y. Ipriflavone in the treatment of postmenopausal osteoporosis: A randomized controlled trial. JAMA 285 (2001) 1482-1488
7. Ammann P. Strontium ranelate: A novel mode of action leading to renewed bone quality. Osteoporos. Int. 16 Suppl. 1 (2005) S11-S15
8. Arai M., Nagasawa T., Koshihara Y., Yamamoto S., and Togari A. Effects of beta-adrenergic agonists on bone-resorbing activity in human osteoclast-like cells. Biochim. Biophys. Acta 1640 (2003) 137-142
9. Arikawa T., Omura K., and Morita I. Regulation of bone morphogenetic protein-2 expression by endogenous prostaglandin E2 in human mesenchymal stem cells. J. Cell. Physiol. 200 (2004) 400-406
10. Armour K.E., Armour K.J., Gallagher M.E., Godecke A., Helfrich M.H., Reid D.M., and Ralston S.H. Defective bone formation and anabolic response to exogenous estrogen in mice with targeted disruption of endothelial nitric oxide synthase. Endocrinology 142 (2001) 760-766
11. Asahina I., Watanabe M., Sakurai N., Mori M., and Enomoto S. Repair of bone defect in primate mandible using a bone morphogenetic protein (BMP)-hydroxyapatite-collagen composite. J. Med. Dent. Sci. 44 (1997) 63-70
12. Aspenberg P., Albrektsson T., and Thorngren K.G. Local application of growth-factor IGF-1 to healing bone. Experiments with a titanium chamber in rabbits. Acta Orthop. Scand. 60 (1989) 607-610
13. Bauer D.C. HMG CoA reductase inhibitors and the skeleton: A comprehensive review. Osteoporos. Int. 14 (2003) 273-282
14. Baumgartner I., and Isner J.M. Stimulation of peripheral angiogenesis by vascular endothelial growth factor (VEGF). Vasa 27 (1998) 201-206
15. Beck L.S., Deguzman L., Lee W.P., Xu Y., McFatridge L.A., Gillett N.A., and Amento E.P. Rapid publication. TGF-beta 1 induces bone closure of skull defects. J. Bone Miner. Res. 6 (1991) 1257-1265
16. Beck L.S., Amento E.P., Xu Y., Deguzman L., Lee W.P., Nguyen T., and Gillett N.A. TGF-beta 1 induces bone closure of skull defects: Temporal dynamics of bone formation in defects exposed to rhTGF-beta 1. J. Bone Miner. Res. 8 (1993) 753-761
17. Bellido T., Ali A.A., Plotkin L.I., Fu Q., Gubrij I., Roberson P.K., Weinstein R.S., O'Brien C.A., Manolagas S.C., and Jilka R.L. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J.Biol. Chem. 278 (2003) 50259-50272
18. Benvenuti S., Tanini A., Frediani U., Bianchi S., Masi L., Casano R., Bufalino L., Serio M., and Brandi M.L. Effects of ipriflavone and its metabolites on a clonal osteoblastic cell line. J. Bone Miner. Res. 6 (1991) 987-996
19. Binderman I., Adut M., and Yaffe A. Effectiveness of local delivery of alendronate in reducing alveolar bone loss following periodontal surgery in rats. J. Periodontol. 71 (2000) 1236-1240
20. Boden S.D. The ABCs of BMPs. Orthop. Nurs. 24 (2005) 49-52 quiz 53-54
21. Boden S.D., Kang J., Sandhu H., and Heller J.G. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: A prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. Spine 27 (2002) 2662-2673
22. Bodine P.V., Billiard J., Moran R.A., Ponce-de-Leon H., McLarney S., Mangine A., Scrimo M.J., Bhat R.A., Stauffer B., Green J., Stein G.S., Lian J.B., et al. The Wnt antagonist secreted frizzled-related protein-1 controls osteoblast and osteocyte apoptosis. J. Cell. Biochem. 96 (2005) 1212-1230
23. Bonewald L.F., Wakefield L., Oreffo R.O., Escobedo A., Twardzik D.R., and Mundy G.R. Latent forms of transforming growth factor-beta (TGF beta) derived from bone cultures: Identification of a naturally occurring 100-kDa complex with similarity to recombinant latent TGF beta. Mol. Endocrinol. 5 (1991) 741-751
24. Bonnet N., Benhamou C.L., Brunet-Imbault B., Arlettaz A., Horcajada M.N., Richard O., Vico L., Collomp K., and Courteix D. Severe bone alterations under beta2 agonist treatments: Bone mass, microarchitecture and strength analyses in female rats. Bone 37 (2005) 622-633
25. Bonucci E., Ballanti P., Martelli A., Mereto E., Brambilla G., Bianco P., and Bufalino L. Ipriflavone inhibits osteoclast differentiation in parathyroid transplanted parietal bone of rats. Calcif. Tissue Int. 50 (1992) 314-319
26. Bonvini P., Hwang S.G., el-Gamil M., Robbins P., Neckers L., and Trepel J. Melanoma cell lines contain a proteasome-sensitive, nuclear cytoskeleton-associated pool of beta-catenin. Ann. N. Y. Acad. Sci. 886 (1999) 208-211
27. Broderick E., Infanger S., Turner T.M., and Sumner D.R. Depressed bone mineralization following high dose TGF-beta1 application in an orthopedic implant model. Calcif. Tissue Int. 76 (2005) 379-384
28. Burstyn-Cohen T., Stanleigh J., Sela-Donenfeld D., and Kalcheim C. Canonical Wnt activity regulates trunk neural crest delamination linking BMP/noggin signaling with G1/S transition. Development 131 (2004) 5327-5339
29. Camelo M., Nevins M.L., Schenk R.K., Lynch S.E., and Nevins M. Periodontal regeneration in human Class II furcations using purified recombinant human platelet-derived growth factor-BB (rhPDGF-BB) with bone allograft. Int. J. Periodontics Restorative Dent. 23 (2003) 213-225
30. Caniggia A., Gennari C., Vattimo A., Runci F., and Bombardieri S. Prostaglandin PGE2: A possible mechanism for bone destruction in calcinosis circumscripta. Calcif. Tissue Res. 25 (1978) 53-57
31. Cao X., and Chen D. The BMP signaling and in vivo bone formation. Gene 357 (2005) 1-8
32. Cardones A.R., and Banez L.L. VEGF inhibitors in cancer therapy. Curr. Pharm. Des. 12 (2006) 387-394
33. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 69 Suppl. 3 (2005) 4-10
34. Cauley J., Jackson R., Pettinger M., LaCroix A., Bauer D., Chen Z., Daugherty S., Hsia J., Lewis C., McGowan J., McNeeley S., and Passaro M. Statin use and bone mineral density (BMD) in older women: The women's health initiative observational study (WH I-OS). J. Bone Miner. Res. 15 Suppl. (2000) 1068
35. Cecchini M.G., Fleisch H., and Muhibauer R.C. Ipriflavone inhibits bone resorption in intact and ovariectomized rats. Calcif. Tissue Int. 61 Suppl. 1 (1997) S9-S11
36. Chan K.A., Andrade S.E., Boles M., Buist D.S., Chase G.A., Donahue J.G., Goodman M.J., Gurwitz J.H., LaCroix A.Z., and Platt R. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 355 (2000) 2185-2188
37. Chan M.H., Mak T.W., Chiu R.W., Chow C.C., Chan I.H., and Lam C.W. Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolaemia. J. Clin. Endocrinol. Metab. 86 (2001) 4556-4559
38. Chang S.C., Wei F.C., Chuang H., Chen Y.R., Chen J.K., Lee K.C., Chen P.K., Tai C.L., and Lou J. Ex vivo gene therapy in autologous critical-size craniofacial bone regeneration. Plast. Reconstr. Surg. 112 (2003) 1841-1850
39. Chiba H., Uehara M., Wu J., Wang X., Masuyama R., Suzuki K., Kanazawa K., and Ishimi Y. Hesperidin, a citrus flavonoid, inhibits bone loss and decreases serum and hepatic lipids in ovariectomized mice. J. Nutr. 133 (2003) 1892-1897
40. Chung Y.S., Lee M.D., Lee S.K., Kim H.M., and Fitzpatrick L.A. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J. Clin. Endocrinol. Metab. 85 (2000) 1137-1142
41. Chyun Y.S., and Raisz L.G. Stimulation of bone formation by prostaglandin E2. Prostaglandins 27 (1984) 97-103
42. Cochran D.L., and Wozney J.M. Biological mediators for periodontal regeneration. Periodontol 2000 19 (1999) 40-58
43. Coffin J.D., Florkiewicz R.Z., Neumann J., Mort-Hopkins T., Dorn II G.W., Lightfoot P., German R., Howles P.N., Kier A., and O'Toole B.A. Abnormal bone growth and selective translational regulation in basic fibroblast growth factor (FGF-2) transgenic mice. Mol. Biol. Cell 6 (1995) 1861-1873
44. Cohen Jr. M.M. The hedgehog signaling network. Am. J. Med. Genet. A 123 (2003) 5-28
45. Compston J., Papapoulos S., and Blanchard F. Report on osteoporosis in the European Community: Current status and recommendations for the future. Working party from European Union member states. Osteoporos. Int. 8 (1998) 531-534
46. Conference-Report F. Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosis. Am. J. Med. 94 (1993) 646-650
47. Crawford D.T., Qi H., Chidesy-Frink K.L., Thompson D.D., and Ke H.Z. Statin increases cortical bone in young male rats by single, local administration but fails to restore bone in ovariectomized (OVX) rats by daily systemic administration. J. Bone Miner. Res. 16 (2001) S295
48. Dailey L., Ambrosetti D., Mansukhani A., and Basilico C. Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev. 16 (2005) 233-247
49. Dakora F.D. Plant flavonoids: Biological molecules for useful exploitation. Aust. J. Plant Physiol. 22 (1995) 87-99
50. Dakora F.D., and Ndakidemi P.A. Legume seed flavonoids and nitrogenous metabolites as signals and protectants in early seedling development. Funct. Plant Biol. 30 (2003) 729-745
51. 2+-sensing receptor (CASR) in the expression of inducible NOS (nitric oxide synthase)-2 and its BH4 (tetrahydrobiopterin)-dependent activation in cytokine-stimulated adult human astrocytes. J. Cell. Biochem. 96 (2005) 428-438
52. de Aloysio D., Gambacciani M., Altieri P., Ciaponi M., Ventura V., Mura M., Genazzani A.R., and Bottiglioni F. Bone density changes in postmenopausal women with the administration of ipriflavone alone or in association with low-dose ERT. Gynecol. Endocrinol. 11 (1997) 289-293
53. Delmas P.D. Clinical effects of strontium ranelate in women with postmenopausal osteoporosis. Osteoporos. Int. 16 Suppl. 1 (2005) S16-S19
54. Deyhim F., Smith B.J., Juma Y., Soung do S., Devareddy L., and Arjmandi B.H. Ipriflavone modulates IGF-I but is unable to restore bone in rats. Phytother. Res. 19 (2005) 116-120
55. Dietrich J.W., and Raisz L.G. Prostaglandin in calcium and bone metabolism. Clin. Orthop. Relat. Res. (1975) 228-237
56. Dieudonne S.C., Foo P., van Zoelen E.J., and Burger E.H. Inhibiting and stimulating effects of TGF-beta 1 on osteoclastic bone resorption in fetal mouse bone organ cultures. J. Bone Miner. Res. 6 (1991) 479-487
57. Dowsett M., Eastman A.R., Easty D.M., Easty G.C., Powles T.J., and Neville A.M. Prostaglandin mediation of collagenase-induced bone resorption. Nature 263 (1976) 72-74
58. Dunstan C.R., Boyce R., Boyce B.F., Garrett I.R., Izbicka E., Burgess W.H., and Mundy G.R. Systemic administration of acidic fibroblast growth factor (FGF-1) prevents bone loss and increases new bone formation in ovariectomized rats. J. Bone Miner. Res. 14 (1999) 953-959
59. Easwaran V., Song V., Polakis P., and Byers S. The ubiquitin-proteasome pathway and serine kinase activity modulate adenomatous polyposis coli protein-mediated regulation of beta-catenin-lymphocyte enhancer-binding factor signaling. J. Biol. Chem. 274 (1999) 16641-16645
60. Edwards C.J., Hart D.J., and Spector T.D. Oral statins and increased bone-mineral density in postmenopausal women. Lancet 355 (2000) 2218-2219
61. Eggenschwiler J.T., Espinoza E., and Anderson K.V. Rab23 is an essential negative regulator of the mouse Sonic hedgehog signalling pathway. Nature 412 (2001) 194-198
62. Eggenschwiler J.T., Bulgakov O.V., Qin J., Li T., and Anderson K.V. Mouse Rab23 regulates hedgehog signaling from smoothened to Gli proteins. Dev. Biol. 290 (2006) 1-12
63. Emmanuele L., Ortmann J., Doerflinger T., Traupe T., and Barton M. Lovastatin stimulates human vascular smooth muscle cell expression of bone morphogenetic protein-2, a potent inhibitor of low-density lipoprotein-stimulated cell growth. Biochem. Biophys. Res. Commun. 302 (2003) 67-72
64. Evans T.M., Ferguson C., Wainwright B.J., Parton R.G., and Wicking C. Rab23, a negative regulator of hedgehog signaling, localizes to the plasma membrane and the endocytic pathway. Traffic 4 (2003) 869-884
65. Evans T.M., Simpson F., Parton R.G., and Wicking C. Characterization of Rab23, a negative regulator of sonic hedgehog signaling. Methods Enzymol. 403 (2005) 759-777
66. Feron O., Dessy C., Desager J.P., and Balligand J.L. Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 103 (2001) 113-118
67. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 69 Suppl. 3 (2005) 11-16
68. Filvaroff E.H. VEGF and bone. J. Musculoskelet. Neuronal Interact. 3 (2003) 304-307 discussion 320-1
69. Fisher M.C., Meyer C., Garber G., and Dealy C.N. Role of IGFBP2, IGF-I and IGF-II in regulating long bone growth. Bone 37 (2005) 741-750
70. Foldes I., Rapcsak M., Szoor A., Gyarmati J., and Szilagyi T. The effect of ipriflavone treatment on osteoporosis induced by immobilization. Acta Morphol. Hung. 36 (1988) 79-93
71. Franke Stenport V., Johansson C.B., Sawase T., Yamasaki Y., and Oida S. FGF-4 and titanium implants: A pilot study in rabbit bone. Clin. Oral Implants Res. 14 (2003) 363-368
72. Funkhouser H.L., Adera T., and Adler R.A. Effect of HMG-CoA reductase inhibitors (statins) on bone mineral density. J. Clin. Densitom. 5 (2002) 151-158
73. Gambacciani M., Spinetti A., Cappagli B., Taponeco F., Felipetto R., Parrini D., Cappelli N., and Fioretti P. Effects of ipriflavone administration on bone mass and metabolism in ovariectomized women. J. Endocrinol. Invest. 16 (1993) 333-337
74. Garrett I.R., Chen D., Gutierrez G., Zhao M., Escobedo A., Rossini G., Harris S.E., Gallwitz W., Kim K.B., Hu S., Crews C.M., and Mundy G.R. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J. Clin. Invest. 111 (2003) 1771-1782
75. Garrett I.R., Gutierrez G., Chen D., et al. Statins stimulate bone formation by enhancing eNOS expression. J. Bone Miner. Res. 16 (2001) S141
76. Garrett I.R., Gutierrez G., and Mundy G.R. Statins and bone formation. Curr. Pharm. Des. 7 (2001) 715-736
77. Ghezzo C., Civitelli R., Cadel S., Borelli G., Maiorino M., Bufalino L., and Bongrani S. Ipriflavone does not alter bone apatite crystal structure in adult male rats. Calcif. Tissue Int. 59 (1996) 496-499
78. Giannobile W.V., Finkelman R.D., and Lynch S.E. Comparison of canine and non-human primate animal models for periodontal regenerative therapy: Results following a single administration of PDGF/IGF-I. J. Periodontol. 65 (1994) 1158-1168
79. Glimcher M.J. A basic architectural principle in the organization of mineralized tissues. Clin. Orthop. Relat. Res. 61 (1968) 16-36
80. Glimcher M.J. The nature of the mineral component of bone and the mechanism of calcification. Instr. Course Lect. 36 (1987) 49-69
81. Grotewold L., and Ruther U. Bmp, Fgf and Wnt signalling in programmed cell death and chondrogenesis during vertebrate limb development: The role of Dickkopf-1. Int. J. Dev. Biol. 46 (2002) 943-947
82. Gullberg B., Johnell O., and Kanis J. World-wide projections for hip fracture. Osteoporos. Int. 7 (1997) 407-413
83. Gutierrez G., Garrett I.R., Rossini G., Castano M., Chapa G., Escobedo A., Esparze J., Horn D., Qiao M., Taylor S., Lalka D., and Mundy G.R. Dermal application of ovastatin to rats causes greater increases in bone formaiton and plasma concentrations than when administered by oral gavage. J. Bone Miner. Res. 15 (2000) S427
84. Gutierrez G.E., Lalka D., Garrett I.R., Rossini G., and Mundy G.R. Transdermal application of lovastatin to rats causes profound increases in bone formation and plasma concentrations. Osteoporos. Int. 17 (2006) 1033-1042
85. Hagino H., Kuraoka M., Kameyama Y., Okano T., and Teshima R. Effect of a selective agonist for prostaglandin E receptor subtype EP4 (ONO-4819) on the cortical bone response to mechanical loading. Bone 36 (2005) 444-453
86. Hagiwara H., Naruse M., Adachi C., Inoue A., Hiruma Y., Otsuka E., Naruse K., Demura H., and Hirose S. Ipriflavone down-regulates endothelin receptor levels during differentiation of rat calvarial osteoblast-like cells. J. Biochem. (Tokyo) 126 (1999) 168-173
87. Harris M., Jenkins M.V., Bennett A., and Wills M.R. Prostaglandin production and bone resorption by dental cysts. Nature 245 (1973) 213-215
88. Harris M., Jenkins M.V., Bennett A., and Wills M.R. Prostaglandin production and bone resorption by the benign intraosseous dental cyst. Clin. Sci. 44 (1973) 24P-25P
89. Hartke J.R., and Lundy M.W. Bone anabolic therapy with selective prostaglandin analogs. J. Musculoskelet. Neuronal Interact. 2 (2001) 25-31
90. Hayashibara T., Hiraga T., Yi B., Nomizu M., Kumagai Y., Nishimura R., and Yoneda T. A synthetic peptide fragment of human MEPE stimulates new bone formation in vitro and in vivo. J. Bone Miner. Res. 19 (2004) 455-462
91. Heldin C.H., and ten Dijke P. SMAD destruction turns off signalling. Nat. Cell Biol. 1 (1999) E195-E197
92. Hoffmann A., and Gross G. BMP signaling pathways in cartilage and bone formation. Crit. Rev. Eukaryot. Gene Expr. 11 (2001) 23-45
93. Holmen S.L., Zylstra C.R., Mukherjee A., Sigler R.E., Faugere M.C., Bouxsein M.L., Deng L., Clemens T.L., and Williams B.O. Essential role of beta-catenin in postnatal bone acquisition. J. Biol. Chem. 280 (2005) 21162-21168
94. Hong L., Tabata Y., Yamamoto M., Miyamoto S., Yamada K., Hashimoto N., and Ikada Y. Comparison of bone regeneration in a rabbit skull defect by recombinant human BMP-2 incorporated in biodegradable hydrogel and in solution. J. Biomater. Sci. Polym. Ed. 9 (1998) 1001-1014
95. Hoppe A., and Rybczynska A. [Calcium receptor (CaR): A new approach to regulation of calcium homeostasis]. Przegl. Lek. 57 (2000) 77-82
96. Horcajada-Molteni M.N., Crespy V., Coxam V., Davicco M.J., Remesy C., and Barlet J.P. Rutin inhibits ovariectomy-induced osteopenia in rats. J. Bone Miner. Res. 15 (2000) 2251-2258
97. Huang H.C., and Klein P.S. Interactions between BMP and Wnt signaling pathways in mammalian cancers. Cancer Biol. Ther. 3 (2004) 676-678
98. Hunninghake D.B. Therapeutic efficacy of the lipid-lowering armamentarium: The clinical benefits of aggressive lipid-lowering therapy. Am. J. Med. 104 (1998) 9S-13S
99. Isgaard J., Nilsson A., Lindahl A., Jansson J.O., and Isaksson O.G. Effects of local administration of GH and IGF-1 on longitudinal bone growth in rats. Am. J. Physiol. 250 (1986) E367-E372
100. Ito H., Ke H.Z., Jee W.S., and Sakou T. Anabolic responses of an adult cancellous bone site to prostaglandin E2 in the rat. Bone Miner. 21 (1993) 219-236
101. Ito M., Nakayama K., Konaka A., Sakata K., Ikeda K., and Maruyama T. Effects of a prostaglandin EP4 agonist, ONO-4819, and risedronate on trabecular microstructure and bone strength in mature ovariectomized rats. Bone 39 3 (2006) 453-459
102. Itoh N., and Ornitz D.M. Evolution of the Fgf and Fgfr gene families. Trends Genet. 20 (2004) 563-569
103. Iwao K., Miyoshi Y., Nawa G., Yoshikawa H., Ochi T., and Nakamura Y. Frequent beta-catenin abnormalities in bone and soft-tissue tumors. Jpn. J. Cancer Res. 90 (1999) 205-209
104. Jee W.S., Mori S., Li X.J., and Chan S. Prostaglandin E2 enhances cortical bone mass and activates intracortical bone remodeling in intact and ovariectomized female rats. Bone 11 (1990) 253-266
105. Jee W.S., Akamine T., Ke H.Z., Li X.J., Tang L.Y., and Zeng Q.Q. Prostaglandin E2 prevents disuse-induced cortical bone loss. Bone 13 (1992) 153-159
106. Johnsen S.A., Subramaniam M., Monroe D.G., Janknecht R., and Spelsberg T.C. Modulation of transforming growth factor beta (TGF beta)/Smad transcriptional responses through targeted degradation of TGF beta-inducible early gene-1 by human seven in absentia homologue. J. Biol. Chem. 277 (2002) 30754-30759
107. Jones C.J., Cummings C., Ball J., and Beighton P. A clinical and ultrastructural study of osteogenesis imperfecta after flavonoid (Catergen) therapy. S. Afr. Med. J. 66 (1984) 907-910
108. Jorgensen H.R., Svanholm H., and Host A. Bone formation induced in an infant by systemic prostaglandin-E2 administration. Acta Orthop. Scand. 59 (1988) 464-466
109. Kakai Y., Kawase T., Nakano T., Mikuni-Takagaki Y., and Saito S. Effect of ipriflavone and estrogen on the differentiation and proliferation of osteogenic cells. Calcif. Tissue Int. 51 Suppl. 1 (1992) S11-S12
110. Kalderon D. Similarities between the hedgehog and Wnt signaling pathways. Trends Cell Biol. 12 (2002) 523-531
111. Kalderon D. The mechanism of hedgehog signal transduction. Biochem. Soc. Trans. 33 (2005) 1509-1512
112. Kanis J. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359 (2002) 1929-1936
113. Kasukawa Y., Miyakoshi N., and Mohan S. The anabolic effects of GH/IGF system on bone. Curr. Pharm. Des. 10 (2004) 2577-2592
114. Kato Y. [Prostaglandin, bone absorption and hypercalcemia]. Kokubyo Gakkai Zasshi 47 (1980) 546
115. Katz J.M., Wilson T., Skinner S.J., and Gray D.H. Bone resorption and prostaglandin production by mouse calvaria in vitro: Response to exogenous prostaglandins and their precursor fatty acids. Prostaglandins 22 (1981) 537-551
116. Kawai S., and Sugiura T. Characterization of human bone morphogenetic protein (BMP)-4 and -7 gene promoters: Activation of BMP promoters by Gli, a sonic hedgehog mediator. Bone 29 (2001) 54-61
117. Kawata T., Tokimasa C., Fujita T., Kaku M., Tsutsui K., Kohno S., Matsuki A., Tenjo K., Ohtani J., Motokawa M., Kobayakawa T., Shigekawa M., et al. Effect of insulin-like growth factor-I (IGF-I) on femoral bone modeling in growing mice. Exp. Anim. 51 (2002) 521-524
118. Kaynak D., Meffert R., Gunhan M., Gunhan O., and Ozkaya O. A histopathological investigation on the effects of the bisphosphonate alendronate on resorptive phase following mucoperiosteal flap surgery in the mandible of rats. J. Periodontol. 71 (2000) 790-796
119. Ke H.Z., Crawford D.T., Qi H., Simmons H.A., Owen T.A., Paralkar V.M., Li M., Lu B., Grasser W.A., Cameron K.O., Lefker B.A., DaSilva-Jardine P., et al. A nonprostanoid EP4 receptor selective prostaglandin E2 agonist restores bone mass and strength in aged, ovariectomized rats. J. Bone Miner. Res. 21 (2006) 565-575
120. Ke H.Z., Jee W.S., Zeng Q.Q., Li M., and Lin B.Y. Prostaglandin E2 increased rat cortical bone mass when administered immediately following ovariectomy. Bone Miner. 21 (1993) 189-201
121. Keller H., and Kneissel M. SOST is a target gene for PTH in bone. Bone 37 (2005) 148-158
122. Kent Leach J., Kaigler D., Wang Z., Krebsbach P.H., and Mooney D.J. Coating of VEGF-releasing scaffolds with bioactive glass for angiogenesis and bone regeneration. Biomaterials 27 (2006) 3249-3255
123. Khan S.N., and Lane J.M. The use of recombinant human bone morphogenetic protein-2 (rhBMP-2) in orthopaedic applications. Expert Opin. Biol. Ther. 4 (2004) 741-748
124. Kimoto T., Hosokawa R., Kubo T., Maeda M., Sano A., and Akagawa Y. Continuous administration of basic fibroblast growth factor (FGF-2) accelerates bone induction on rat calvaria-an application of a new drug delivery system. J. Dent. Res. 77 (1998) 1965-1969
125. Kleinheinz J., Stratmann U., Joos U., and Wiesmann H.P. VEGF-activated angiogenesis during bone regeneration. J. Oral Maxillofac. Surg. 63 (2005) 1310-1316
126. Komatsubara S., and Mori S. [Bone quality in fracture callus]. Clin. Calcium 15 (2005) 977-983
127. Kovacs A.B. Efficacy of ipriflavone in the prevention and treatment of postmenopausal osteoporosis. Agents Actions 41 (1994) 86-87
128. Kusu N., Laurikkala J., Imanishi M., Usui H., Konishi M., Miyake A., Thesleff I., and Itoh N. Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J. Biol. Chem. 278 (2003) 24113-24117
129. LaCroix A.Z., Cauley J.A., Pettinger M., Hsia J., Bauer D.C., McGowan J., Chen Z., Lewis C.E., McNeeley S.G., Passaro M.D., and Jackson R.D. Statin use, clinical fracture, and bone density in postmenopausal women: Results from the women's health initiative observational study. Ann. Intern. Med. 139 (2003) 97-104
130. Laufs U., Fata V.L., and Liao J.K. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J. Biol. Chem. 272 (1997) 31725-31729
131. Li G., Ryaby J.T., Carney D.H., and Wang H. Bone formation is enhanced by thrombin-related peptide TP508 during distraction osteogenesis. J. Orthop. Res. 23 (2005) 196-202
132. Li J., Li H., Kadota S., Namba T., Miyahara T., and Khan U.G. Effects on cultured neonatal mouse calvaria of the flavonoids isolated from Boerhaavia repens. J. Nat. Prod. 59 (1996) 1015-1018
133. Li M., Jee W.S., Ke H.Z., Liang X.G., Lin B.Y., Ma Y.F., and Setterberg R.B. Prostaglandin E2 restores cancellous bone to immobilized limb and adds bone to overloaded limb in right hindlimb immobilization rats. Bone 14 (1993) 283-288
134. Li M., Jee W.S., Ke H.Z., Tang L.Y., Ma Y.F., Liang X.G., and Setterberg R.B. Prostaglandin E2 administration prevents bone loss induced by orchidectomy in rats. J. Bone Miner. Res. 10 (1995) 66-73
135. Li R.H., Bouxsein M.L., Blake C.A., D'Augusta D., Kim H., Li X.J., Wozney J.M., and Seeherman H.J. rhBMP-2 injected in a calcium phosphate paste (alpha-BSM) accelerates healing in the rabbit ulnar osteotomy model. J. Orthop. Res. 21 (2003) 997-1004
136. Linkhart T.A., Mohan S., and Baylink D.J. Growth factors for bone growth and repair: IGF, TGF beta and BMP. Bone 19 (1996) 1S-12S
137. Litsiou A., Hanson S., and Streit A. A balance of FGF, BMP and WNT signalling positions the future placode territory in the head. Development 132 (2005) 4051-4062
138. Lorenzo J.A., and Sousa S. Phorbol esters stimulate bone resorption in fetal rat long-bone cultures by mechanisms independent of prostaglandin synthesis. J. Bone Miner. Res. 3 (1988) 63-67
139. Luckman S.P., Hughes D.E., Coxon F.P., Graham R., Russell G., and Rogers M.J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res. 13 (1998) 581-589
140. Ma Y.F., Ke H.Z., and Jee W.S. Prostaglandin E2 adds bone to a cancellous bone site with a closed growth plate and low bone turnover in ovariectomized rats. Bone 15 (1994) 137-146
141. Maeda T., Matsunuma A., Kawane T., and Horiuchi N. Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem. Biophys. Res. Commun. 280 (2001) 874-877
142. Maeda T., Matsunuma A., Kurahashi I., Yanagawa T., Yoshida H., and Horiuchi N. Induction of osteoblast differentiation indices by statins in MC3T3-E1 cells. J. Cell. Biochem. 92 (2004) 458-471
143. Majeska R.J., Minkowitz B., Bastian W., and Einhorn T.A. Effects of beta-adrenergic blockade in an osteoblast-like cell line. J. Orthop. Res. 10 (1992) 379-384
144. Marie P. Growth factors and bone formation in osteoporosis: Roles for IGF-I and TGF-beta. Rev. Rhum. Engl. Ed. 64 (1997) 44-53
145. Marie P.J. Strontium ranelate: A novel mode of action optimizing bone formation and resorption. Osteoporos. Int. 16 Suppl. 1 (2005) S7-S10
146. Marks Jr. S.C., and Miller S. Local infusion of prostaglandin E1 stimulates mandibular bone formation in vivo. J. Oral Pathol. 17 (1988) 500-505
147. Matsuo T., Sugita T., Kubo T., Yasunaga Y., Ochi M., and Murakami T. Injectable magnetic liposomes as a novel carrier of recombinant human BMP-2 for bone formation in a rat bone-defect model. J. Biomed. Mater. Res. A 66 (2003) 747-754
148. Mazzuoli G., Romagnoli E., Carnevale V., Scarda A., Scarnecchia L., Pacitti M.T., Rosso R., and Minisola S. Effects of ipriflavone on bone remodeling in primary hyperparathyroidism. Bone Miner. 19 Suppl. 1 (1992) S27-S33
149. Mbalaviele G., Sheikh S., Stains J.P., Salazar V.S., Cheng S.L., Chen D., and Civitelli R. Beta-catenin and BMP-2 synergize to promote osteoblast differentiation and new bone formation. J. Cell. Biochem. 94 (2005) 403-418
150. McCarthy T.L., and Centrella M. Local IGF-I expression and bone formation. Growth Horm. IGF Res. 11 (2001) 213-219
151. McCarthy T.L., Centrella M., and Canalis E. Insulin-like growth factor (IGF) and bone. Connect. Tissue Res. 20 (1989) 277-282
152. McCarthy T.L., Centrella M., Raisz L.G., and Canalis E. Prostaglandin E2 stimulates insulin-like growth factor I synthesis in osteoblast-enriched cultures from fetal rat bone. Endocrinology 128 (1991) 2895-2900
153. Meier C.R., Schlienger R.G., Kraenzlin M.E., Schlegel B., and Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 283 (2000) 3205-3210
154. Meier C.R., Schlienger R.G., Kraenzlin M.E., Schlegel B., and Jick H. Statin drugs and the risk of fracture. JAMA 284 (2000) 1921-1922
155. Melis G.B., Paoletti A.M., Bartolini R., Tosti Balducci M., Massi G.B., Bruni V., Becorpi A., Ottanelli S., Fioretti P., Gambacciani M., Spinetti A., D'Antona N., et al. Ipriflavone and low doses of estrogens in the prevention of bone mineral loss in climacterium. Bone Miner 19 Suppl. 1 (1992) S49-S56
156. Melton L.I., Chrischilles E., Cooper C., Lane A., and Riggs B. Perspective: How many women have osteoporosis?. J. Bone Miner. Res. 7 (1992) 1005-1010
157. Melton III L.J. The prevalence of osteoporosis. J. Bone Miner. Res. 12 (1997) 1769-1771
158. Miller S.C., and Marks Jr. S.C. Alveolar bone augmentation following the local administration of prostaglandin E1 by controlled-release pellets. Bone 14 (1993) 587-593
159. Miller S.C., and Marks Jr. S.C. Local stimulation of new bone formation by prostaglandin E1: Quantitative histomorphometry and comparison of delivery by minipumps and controlled-release pellets. Bone 14 (1993) 143-151
160. Ming X.F., Viswambharan H., Barandier C., Ruffieux J., Kaibuchi K., Rusconi S., and Yang Z. Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol. Cell Biol. 22 (2002) 8467-8477
161. Minkowitz B., Boskey A.L., Lane J.M., Pearlman H.S., and Vigorita V.J. Effects of propranolol on bone metabolism in the rat. J. Orthop. Res. 9 (1991) 869-875
162. Mitlak B.H., Finkelman R.D., Hill E.L., Li J., Martin B., Smith T., D'Andrea M., Antoniades H.N., and Lynch S.E. The effect of systemically administered PDGF-BB on the rodent skeleton. J. Bone Miner. Res. 11 (1996) 238-247
163. Miyake M., Arai N., Ushio S., Iwaki K., Ikeda M., and Kurimoto M. Promoting effect of kaempferol on the differentiation and mineralization of murine pre-osteoblastic cell line MC3T3-E1. Biosci. Biotechnol. Biochem. 67 (2003) 1199-1205
164. Miyakoshi N., Qin X., Kasukawa Y., Richman C., Srivastava A.K., Baylink D.J., and Mohan S. Systemic administration of insulin-like growth factor (IGF)-binding protein-4 (IGFBP-4) increases bone formation parameters in mice by increasing IGF bioavailability via an IGFBP-4 protease-dependent mechanism. Endocrinology 142 (2001) 2641-2648
165. Mori S., Jee W.S., Li X.J., Chan S., and Kimmel D.B. Effects of prostaglandin E2 on production of new cancellous bone in the axial skeleton of ovariectomized rats. Bone 11 (1990) 103-113
166. Mori S., Jee W.S., and Li X.J. Production of new trabecular bone in osteopenic ovariectomized rats by prostaglandin E2. Calcif. Tissue Int. 50 (1992) 80-87
167. Moxham J.P., Kibblewhite D.J., Dvorak M., Perey B., Tencer A.F., Bruce A.G., and Strong D.M. TGF-beta 1 forms functionally normal bone in a segmental sheep tibial diaphyseal defect. J. Otolaryngol. 25 (1996) 388-392
168. Mundy G.R. The effects of TGF-beta on bone. Ciba Found. Symp. 157 (1991) 137-143 143-51 (discussion)
169. Mundy G., Garrett R., Harris S., Chan J., Chen D., Rossini G., Boyce B., Zhao M., and Gutierrez G. Stimulation of bone formation in vitro and in rodents by statins. Science 286 (1999) 1946-1949
170. Murakami N., Saito N., Horiuchi H., Okada T., Nozaki K., and Takaoka K. Repair of segmental defects in rabbit humeri with titanium fiber mesh cylinders containing recombinant human bone morphogenetic protein-2 (rhBMP-2) and a synthetic polymer. J. Biomed. Mater. Res. 62 (2002) 169-174
171. Nagel D.E., Khosla S., Sanyal A., Rosen D.M., Kumagai Y., and Riggs B.L. A fragment of the hypophosphatemic factor, MEPE, requires inducible cyclooxygenase-2 to exert potent anabolic effects on normal human marrow osteoblast precursors. J. Cell. Biochem. 93 (2004) 1107-1114
172. Nakai D., Nakagomi R., Furuta Y., Tokui T., Abe T., Ikeda T., and Nishimura K. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J. Pharmacol. Exp. Ther. 297 (2001) 861-867
173. Nakamae A., Sunagawa T., Ishida O., Suzuki O., Yasunaga Y., Hachisuka H., and Ochi M. Acceleration of surgical angiogenesis in necrotic bone with a single injection of fibroblast growth factor-2 (FGF-2). J. Orthop. Res. 22 (2004) 509-513
174. Nakamura S., Morimoto S., Takamoto S., Onishi T., Fukuo K., Koh E., Kitano S., Miyashita Y., Yasuda O., Tamatani M., Nakahashi T., and Ogihara T. Effect of ipriflavone on bone mineral density and calcium-related factors in elderly females. Calcif. Tissue Int. 51 Suppl. 1 (1992) S30-S34
175. Nemeth E.F. Pharmacological regulation of parathyroid hormone secretion. Curr. Pharm. Des. 8 (2002) 2077-2087
176. Nemeth E.F. The search for calcium receptor antagonists (calcilytics). J. Mol. Endocrinol. 29 (2002) 15-21
177. Nemeth E.F. Calcimimetic and calcilytic drugs: Just for parathyroid cells?. Cell Calcium 35 (2004) 283-289
178. Nemeth E.F. Summary--calcium receptors: Potential targets for novel treatments for skeletal disease. J. Musculoskelet. Neuronal Interact. 4 (2004) 416-417
179. 2+ receptor antagonists that stimulate secretion of parathyroid hormone. J. Pharmacol. Exp. Ther. 299 (2001) 323-331
180. Nevins M., Camelo M., Nevins M.L., Schenk R.K., and Lynch S.E. Periodontal regeneration in humans using recombinant human platelet-derived growth factor-BB (rhPDGF-BB) and allogenic bone. J. Periodontol. 74 (2003) 1282-1292
181. Nevins M., Giannobile W.V., McGuire M.K., Kao R.T., Mellonig J.T., Hinrichs J.E., McAllister B.S., Murphy K.S., McClain P.K., Nevins M.L., Paquette D.W., Han T.J., et al. Platelet-derived growth factor stimulates bone fill and rate of attachment level gain: Results of a large multicenter randomized controlled trial. J. Periodontol. 76 (2005) 2205-2215
182. Nishimori S., Tanaka Y., Chiba T., Fujii M., Imamura T., Miyazono K., Ogasawara T., Kawaguchi H., Igarashi T., Fujita T., Tanaka K., and Toyoshima H. Smad-mediated transcription is required for transforming growth factor-beta 1-induced p57(Kip2) proteolysis in osteoblastic cells. J. Biol. Chem. 276 (2001) 10700-10705
183. Norfleet A.M., Bergmann J.S., and Carney D.H. Thrombin peptide, TP508, stimulates angiogenic responses in animal models of dermal wound healing, in chick chorioallantoic membranes, and in cultured human aortic and microvascular endothelial cells. Gen. Pharmacol. 35 (2000) 249-254
184. NPS. NPS web site (2006)
185. Ohyama Y., Nifuji A., Maeda Y., Amagasa T., and Noda M. Spaciotemporal association and bone morphogenetic protein regulation of sclerostin and osterix expression during embryonic osteogenesis. Endocrinology 145 (2004) 4685-4692
186. Orthologic. Orthologic Web Site - 4-10-06 (2006)
187. Ott S.M. Sclerostin and Wnt signaling-the pathway to bone strength. J. Clin. Endocrinol. Metab. 90 (2005) 6741-6743
188. Oxlund H., and Andreassen T.T. Simvastatin treatment partially prevents ovariectomy-induced bone loss while increasing cortical bone formation. Bone 34 (2004) 609-618
189. Ozawa H., Nakamura H., Irie K., and Irie M. Histochemical and fine structural study of bone of ipriflavone-treated rats. Calcif. Tissue Int. 51 Suppl. 1 (1992) S21-S26
190. Paralkar V.M., Borovecki F., Ke H.Z., Cameron K.O., Lefker B., Grasser W.A., Owen T.A., Li M., DaSilva-Jardine P., Zhou M., Dunn R.L., Dumont F., et al. An EP2 receptor-selective prostaglandin E2 agonist induces bone healing. Proc. Natl. Acad. Sci. USA 100 (2003) 6736-6740
191. Pasco J.A., Kotowicz M.A., Henry M.J., Sanders K.M., and Nicholson G.C. Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study. Arch. Intern. Med. 162 (2002) 537-540
192. Pasco J.A., Henry M.J., Sanders K.M., Kotowicz M.A., Seeman E., and Nicholson G.C. Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study. J. Bone Miner. Res. 19 (2004) 19-24
193. Pasco J.A., Henry M.J., Nicholson G.C., Schneider H.G., and Kotowicz M.A. Beta-blockers reduce bone resorption marker in early postmenopausal women. Ann. Hum. Biol. 32 (2005) 738-745
194. Passeri M., Biondi M., Costi D., Bufalino L., Castiglione G.N., Di Peppe C., and Abate G. Effect of ipriflavone on bone mass in elderly osteoporotic women. Bone Miner. 19 Suppl. 1 (1992) S57-S62
195. Paszty C. Anti-SOST as an anabolic therapy for bone. Bone Workshops, Davos 2006. Abstracts from the workshop: Frontiers of skeletal biology workshop on cell biology of bone and cartilage in health and disease, Davos, Switzerland, March 18-22, 2006. Bone 38 (2006) (Suppl. 1)
196. Peng H., Wright V., Usas A., Gearhart B., Shen H.C., Cummins J., and Huard J. Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4. J. Clin. Invest. 110 (2002) 751-759
197. Peng H., Usas A., Olshanski A., Ho A.M., Gearhart B., Cooper G.M., and Huard J. VEGF improves, whereas sFlt1 inhibits, BMP2-induced bone formation and bone healing through modulation of angiogenesis. J. Bone Miner. Res. 20 (2005) 2017-2027
198. Poole K.E., van Bezooijen R.L., Loveridge N., Hamersma H., Papapoulos S.E., Lowik C.W., and Reeve J. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 19 (2005) 1842-1844
199. Prouillet C., Maziere J.C., Maziere C., Wattel A., Brazier M., and Kamel S. Stimulatory effect of naturally occurring flavonols quercetin and kaempferol on alkaline phosphatase activity in MG-63 human osteoblasts through ERK and estrogen receptor pathway. Biochem. Pharmacol. 67 (2004) 1307-1313
200. Raible D.W., and Ragland J.W. Reiterated Wnt and BMP signals in neural crest development. Semin. Cell Dev. Biol. 16 (2005) 673-682
201. Raisz L.G., and Fall P.M. Biphasic effects of prostaglandin E2 on bone formation in cultured fetal rat calvariae: Interaction with cortisol. Endocrinology 126 (1990) 1654-1659
202. Raisz L.G., and Koolemans-Beynen A.R. Inhibition of bone collagen synthesis by prostaglandin E2 in organ culture. Prostaglandins 8 (1974) 377-385
203. Raisz L.G., Sandberg A.L., Goodson J.M., Simmons H.A., and Mergenhagen S.E. Complement-dependent stimulation of prostaglandin synthesis and bone resorption. Science 185 (1974) 789-791
204. Raisz L.G., Vanderhoek J.Y., Simmons H.A., Kream B.E., and Nicolaou K.C. Prostaglandin synthesis by fetal rat bone in vitro: Evidence for a role of prostacyclin. Prostaglandins 17 (1979) 905-914
205. Raisz L.G., Fall P.M., Gabbitas B.Y., McCarthy T.L., Kream B.E., and Canalis E. Effects of prostaglandin E2 on bone formation in cultured fetal rat calvariae: Role of insulin-like growth factor-I. Endocrinology 133 (1993) 1504-1510
206. Raisz L.G., and Woodiel F.N. Effects of selective prostaglandin EP2 and EP4 receptor agonists on bone resorption and formation in fetal rat organ cultures. Prostaglandins Other Lipid Mediat. 71 (2003) 287-292
207. Rassi C.M., Lieberherr M., Chaumaz G., Pointillart A., and Cournot G. Modulation of osteoclastogenesis in porcine bone marrow cultures by quercetin and rutin. Cell Tissue Res. 319 (2005) 383-393
208. Rawadi G., Vayssiere B., Dunn F., Baron R., and Roman-Roman S. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J. Bone Miner. Res. 18 (2003) 1842-1853
209. Reginster J.Y. Ipriflavone: Pharmacological properties and usefulness in postmenopausal osteoporosis. Bone Miner. 23 (1993) 223-232
210. Reginster J.Y. Strontium ranelate in osteoporosis. Curr. Pharm. Des. 8 (2002) 1907-1916
211. Reginster J.Y., Deroisy R., and Jupsin I. Strontium ranelate: A new paradigm in the treatment of osteoporosis. Drugs Today (Barc.) 39 (2003) 89-101
212. Reid I.R., Gamble G.D., Grey A.B., Black D.M., Ensrud K.E., Browner W.S., and Bauer D.C. Beta-blocker use, BMD, and fractures in the study of osteoporotic fractures. J. Bone Miner. Res. 20 (2005) 613-618
213. Rejnmark L., Buus N.H., Vestergaard P., Andreasen F., Larsen M.L., and Mosekilde L. Statins decrease bone turnover in postmenopausal women: A cross-sectional study. Eur. J. Clin. Invest. 32 (2002) 581-589
214. Rejnmark L., Buus N.H., Vestergaard P., Heickendorff L., Andreasen F., Larsen M.L., and Mosekilde L. Effects of simvastatin on bone turnover and BMD: A 1-year randomized controlled trial in postmenopausal osteopenic women. J. Bone Miner. Res. 19 (2004) 737-744
215. Ribari O., and Sziklai I. Effect of flavonoid on PGE2-induced alterations in percentage collagen synthesis in ossicle organ cultures. Acta Otolaryngol. 103 (1987) 657-660
216. Rizzoli R. A new treatment for post-menopausal osteoporosis: Strontium ranelate. J. Endocrinol. Invest. 28 (2005) 50-57
217. Robinson D.R., Tashjian Jr. A.H., and Levine L. Prostaglandin-induced bone resorption by rheumatoid synovia. Trans. Assoc. Am. Physicians 88 (1975) 146-160
218. Ross C.M. Quercetin, fruit consumption, and bone mineral density. Am. J. Clin. Nutr. 81 (2005) 1176 author reply 1176
219. Rowe P.S., Kumagai Y., Gutierrez G., Garrett I.R., Blacher R., Rosen D., Cundy J., Navvab S., Chen D., Drezner M.K., Quarles L.D., and Mundy G.R. MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 34 (2004) 303-319
220. Sakamoto S., Sakamoto M., Goldhaber P., and Glimcher M.J. Collagenase activity and morphological and chemical bone resorption induced by prostaglandin E2 in tissue culture. Proc. Soc. Exp. Biol. Med. 161 (1979) 99-103
221. Salomon D., Sacco P.A., Roy S.G., Simcha I., Johnson K.R., Wheelock M.J., and Ben-Ze'ev A. Regulation of beta-catenin levels and localization by overexpression of plakoglobin and inhibition of the ubiquitin-proteasome system. J. Cell Biol. 139 (1997) 1325-1335
222. Sandhu H. Spinal fusion using bone morphogenetic proteins. Orthopedics 27 (2004) 717-718
223. Schilephake H. Bone growth factors in maxillofacial skeletal reconstruction. Int. J. Oral Maxillofac. Surg. 31 (2002) 469-484
224. Schlienger R.G., Kraenzlin M.E., Jick S.S., and Meier C.R. Use of beta-blockers and risk of fractures. JAMA 292 (2004) 1326-1332
225. Schmid C., Schlapfer I., Waldvogel M., Zapf J., and Froesch E.R. Prostaglandin E2 stimulates synthesis of insulin-like growth factor binding protein-3 in rat bone cells in vitro. J. Bone Miner. Res. 7 (1992) 1157-1163
226. Schmitt C.P., Homme M., and Schaefer F. Structural organization and biological relevance of oscillatory parathyroid hormone secretion. Pediatr. Nephrol. 20 (2005) 346-351
227. Schwartz Z., Carney D.H., Crowther R.S., Ryaby J.T., and Boyan B.D. Thrombin peptide (TP508) treatment of rat growth plate cartilage cells promotes proliferation and retention of the chondrocytic phenotype while blocking terminal endochondral differentiation. J. Cell. Physiol. 202 (2005) 336-343
228. Scranton R.E., Young M., Lawler E., Solomon D., Gagnon D., and Gaziano J.M. Statin use and fracture risk: Study of a US veterans population. Arch. Intern. Med. 165 (2005) 2007-2012
229. Shamir D., Keila S., and Weinreb M. A selective EP4 receptor antagonist abrogates the stimulation of osteoblast recruitment from bone marrow stromal cells by prostaglandin E2 in vivo and in vitro. Bone 34 (2004) 157-162
230. Shcherbakova I., Balandrin M.F., Fox J., Ghatak A., Heaton W.L., and Conklin R.L. 3H-Quinazolin-4-ones as a new calcilytic template for the potential treatment of osteoporosis. Bioorg. Med. Chem. Lett. 15 (2005) 1557-1560
231. Shcherbakova I., Huang G., Geoffroy O.J., Nair S.K., Swierczek K., Balandrin M.F., Fox J., Heaton W.L., and Conklin R.L. Design, new synthesis, and calcilytic activity of substituted 3H-pyrimidin-4-ones. Bioorg. Med. Chem. Lett. 15 (2005) 2537-2540
232. Sheller M.R., Crowther R.S., Kinney J.H., Yang J., Di Jorio S., Breunig T., Carney D.H., and Ryaby J.T. Repair of rabbit segmental defects with the thrombin peptide, TP508. J. Orthop. Res. 22 (2004) 1094-1099
233. Shen R., Chen M., Wang Y.J., Kaneki H., Xing L., O'Keefe R.J., and Chen D. Smad6 interacts with Runx2 and mediates Smad ubiquitin regulatory factor 1-induced Runx2 degradation. J. Biol. Chem. 281 (2006) 3569-3576
234. Shimazaki C., Uchida R., Nakano S., Namura K., Fuchida S.I., Okano A., Okamoto M., and Inaba T. High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: Possible role of bortezomib on osteoblast differentiation. Leukemia 19 (2005) 1102-1103
235. Shino A., Tsukuda R., Odaka H., Kitazaki T., Tsuda M., and Matsuo T. Suppressive effect of ipriflavone on bone depletion in the experimental diabetic rat: Dose response of ipriflavone. Life Sci. 42 (1988) 1123-1130
236. Singh R., Kumar P., and Gupta P.P. Comparative functional characterization of mouse bone marrow-derived mast cells and peritoneal mast cells in response to non-immunological stimuli. Indian J. Exp. Biol. 39 (2001) 323-328
237. Skoglund B., and Aspenberg P. Local application of simvastatin imporves fracture healing in mice. Transactions 31 (2006) Abstract #1667
238. Skoglund B., Forslund C., and Aspenberg P. Simvastatin improves fracture healing in mice. J. Bone Miner. Res. 17 (2002) 2004-2008
239. Son Y.O., Kook S.H., Choi K.C., Jang Y.S., Jeon Y.M., Kim J.G., Lee K.Y., Kim J., Chung M.S., Chung G.H., and Lee J.C. Quercetin, a bioflavonoid, accelerates TNF-alpha-induced growth inhibition and apoptosis in MC3T3-E1 osteoblastic cells. Eur. J. Pharmacol. 529 (2006) 24-32
240. Southwood L.L., Frisbie D.D., Kawcak C.E., Ghivizzani S.C., Evans C.H., and McIlwraith C.W. Evaluation of Ad-BMP-2 for enhancing fracture healing in an infected defect fracture rabbit model. J. Orthop. Res. 22 (2004) 66-72
241. Spin J.M., and Vagelos R.H. Early use of statins in acute coronary syndromes. Curr. Atheroscler. Rep. 5 (2003) 44-51
242. Springer I.N., Acil Y., Kuchenbecker S., Bolte H., Warnke P.H., Abboud M., Wiltfang J., and Terheyden H. Bone graft versus BMP-7 in a critical size defect-cranioplasty in a growing infant model. Bone 37 (2005) 563-569
243. Stabnov L., Kasukawa Y., Guo R., Amaar Y., Wergedal J.E., Baylink D.J., and Mohan S. Effect of insulin-like growth factor-1 (IGF-1) plus alendronate on bone density during puberty in IGF-1-deficient MIDI mice. Bone 30 (2002) 909-916
244. Stiernberg J., Norfleet A.M., Redin W.R., Warner W.S., Fritz R.R., and Carney D.H. Acceleration of full-thickness wound healing in normal rats by the synthetic thrombin peptide, TP508. Wound Repair Regen. 8 (2000) 204-215
245. Sugiyama M., Kodama T., Konishi K., Abe K., Asami S., and Oikawa S. Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem. Biophys. Res. Commun. 271 (2000) 688-692
246. Sutherland M.K., Geoghegan J.C., Yu C., Turcott E., Skonier J.E., Winkler D.G., and Latham J.A. Sclerostin promotes the apoptosis of human osteoblastic cells: A novel regulation of bone formation. Bone 35 (2004) 828-835
247. Sziklai I., and Ribari O. Flavonoids alter bone-remodelling in auditory ossicle organ cultures. Acta Otolaryngol. 115 (1995) 296-299
248. Takeuchi T., Tsuboi T., Arai M., and Togari A. Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells. Biochem. Pharmacol. 61 (2001) 579-586
249. Tanaka M., Sakai A., Uchida S., Tanaka S., Nagashima M., Katayama T., Yamaguchi K., and Nakamura T. Prostaglandin E2 receptor (EP4) selective agonist (ONO-4819.CD) accelerates bone repair of femoral cortex after drill-hole injury associated with local upregulation of bone turnover in mature rats. Bone 34 (2004) 940-948
250. Tashjian Jr. A.H., and Levine L. Epidermal growth factor stimulates prostaglandin production and bone resorption in cultured mouse calvaria. Biochem. Biophys. Res. Commun. 85 (1978) 966-975
251. Tashjian Jr. A.H., Voelkel E.F., Levine L., and Goldhaber P. Evidence that the bone resorption-stimulating factor produced by mouse fibrosarcoma cells is prostaglandin E2. A new model for the hypercalcemia of cancer. J. Exp. Med. 136 (1972) 1329-1343
252. Tashjian Jr. A.H., Tice J.E., and Sides K. Biological activities of prostaglandin analogues and metabolites on bone in organ culture. Nature 266 (1977) 645-647
253. Theil T., Aydin S., Koch S., Grotewold L., and Ruther U. Wnt and Bmp signalling cooperatively regulate graded Emx2 expression in the dorsal telencephalon. Development 129 (2002) 3045-3054
254. Thylin M.R., McConnell J.C., Schmid M.J., Reckling R.R., Ojha J., Bhattacharyya I., Marx D.B., and Reinhardt R.A. Effects of simvastatin gels on murine calvarial bone. J. Periodontol. 73 (2002) 1141-1148
255. Tian Q., He X.C., Hood L., and Li L. Bridging the BMP and Wnt pathways by PI3 kinase/Akt and 14-3-3zeta. Cell Cycle 4 (2005) 215-216
256. Tintut Y., Parhami F., Le V., Karsenty G., and Demer L.L. Inhibition of osteoblast-specific transcription factor Cbfa1 by the cAMP pathway in osteoblastic cells. Ubiquitin/proteasome-dependent regulation. J. Biol. Chem. 274 (1999) 28875-28879
257. Toyoda H., Terai H., Sasaoka R., Oda K., and Takaoka K. Augmentation of bone morphogenetic protein-induced bone mass by local delivery of a prostaglandin E EP4 receptor agonist. Bone 37 (2005) 555-562
258. Tsopanoglou N.E., Papaconstantinou M.E., Flordellis C.S., and Maragoudakis M.E. On the mode of action of thrombin-induced angiogenesis: Thrombin peptide, TP508, mediates effects in endothelial cells via alphavbeta3 integrin. Thromb. Haemost. 92 (2004) 846-857
259. Tuli R., Seghatoleslami M.R., Tuli S., Howard M.S., Danielson K.G., and Tuan R.S. p38 MAP kinase regulation of AP-2 binding in TGF-beta1-stimulated chondrogenesis of human trabecular bone-derived cells. Ann. N. Y. Acad. Sci. 961 (2002) 172-177
260. Tzahor E., Kempf H., Mootoosamy R.C., Poon A.C., Abzhanov A., Tabin C.J., Dietrich S., and Lassar A.B. Antagonists of Wnt and BMP signaling promote the formation of vertebrate head muscle. Genes Dev. 17 (2003) 3087-3099
261. Urano T. [Wnt-beta-catenin signaling in bone metabolism]. Clin. Calcium 16 (2006) 54-60
262. Urist M.R., Mikulski A.J., Nakagawa M., and Yen K. A bone matrix calcification-initiator noncollagenous protein. Am. J. Physiol. 232 (1977) C115-C127
263. Urist M.R., Mikulski A., and Lietze A. Solubilized and insolubilized bone morphogenetic protein. Proc. Natl. Acad. Sci. USA 76 (1979) 1828-1832
264. Urist M.R., Lietze A., Mizutani H., Takagi K., Triffitt J.T., Amstutz J., DeLange R., Termine J., and Finerman G.A. A bovine low molecular weight bone morphogenetic protein (BMP) fraction. Clin. Orthop. Relat. Res. 21 (1982) 9-232
265. van Bezooijen R.L., Roelen B.A., Visser A., van der Wee-Pals L., de Wilt E., Karperien M., Hamersma H., Papapoulos S.E., ten Dijke P., and Lowik C.W. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J. Exp. Med. 199 (2004) 805-814
266. van Bezooijen R.L., Papapoulos S.E., and Lowik C.W. Bone morphogenetic proteins and their antagonists: The sclerostin paradigm. J. Endocrinol. Invest. 28 (2005) 15-17
267. van Bezooijen R.L., ten Dijke P., Papapoulos S.E., and Lowik C.W. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev. 16 (2005) 319-327
268. van den Heuvel M. Hedgehog signalling: Off the shelf modulation. Curr. Biol. 13 (2003) R686-R688
269. van der Horst G., Farih-Sips H., Lowik C.W., and Karperien M. Multiple mechanisms are involved in inhibition of osteoblast differentiation by PTHrP and PTH in KS483 cells. J. Bone Miner. Res. 20 (2005) 2233-2244
270. van Staa T.P., Wegman S., de Vries F., Leufkens B., and Cooper C. Use of statins and risk of fractures. JAMA 285 (2001) 1850-1855
271. Varley J.E., and Maxwell G.D. BMP-2 and BMP-4, but not BMP-6, increase the number of adrenergic cells which develop in quail trunk neural crest cultures. Exp. Neurol. 140 (1996) 84-94
272. Varley J.E., McPherson C.E., Zou H., Niswander L., and Maxwell G.D. Expression of a constitutively active type I BMP receptor using a retroviral vector promotes the development of adrenergic cells in neural crest cultures. Dev. Biol. 196 (1998) 107-118
273. Vaya J., and Tamir S. The relation between the chemical structure of flavonoids and their estrogen-like activities. Curr. Med. Chem. 11 (2004) 1333-1343
274. Wan M., and Cao X. BMP signaling in skeletal development. Biochem. Biophys. Res. Commun. 328 (2005) 651-657
275. Wang H., Li X., Tomin E., Doty S.B., Lane J.M., Carney D.H., and Ryaby J.T. Thrombin peptide (TP508) promotes fracture repair by up-regulating inflammatory mediators, early growth factors, and increasing angiogenesis. J. Orthop. Res. 23 (2005) 671-679
276. Wang P.S., Solomon D.H., Mogun H., and Avorn J. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 283 (2000) 3211-3216
277. Wattel A., Kamel S., Mentaverri R., Lorget F., Prouillet C., Petit J.P., Fardelonne P., and Brazier M. Potent inhibitory effect of naturally occurring flavonoids quercetin and kaempferol on in vitro osteoclastic bone resorption. Biochem. Pharmacol. 65 (2003) 35-42
278. Wattel A., Kamel S., Prouillet C., Petit J.P., Lorget F., Offord E., and Brazier M. Flavonoid quercetin decreases osteoclastic differentiation induced by RANKL via a mechanism involving NF kappa B and AP-1. J. Cell. Biochem. 92 (2004) 285-295
279. Whang K., McDonald J., Khan A., and Satsangi N. A novel osteotropic biomaterial OG-PLG: Synthesis and in vitro release. J. Biomed. Mater. Res. A 74 (2005) 237-246
280. WHO. The Burden of Musculoskeletal Conditions at the Start of the Millennium. Technical report series. Geneva, WHO 919 (2003)
281. Wildemann B., Kandziora F., Krummrey G., Palasdies N., Haas N.P., Raschke M., and Schmidmaier G. Local and controlled release of growth factors (combination of IGF-I and TGF-beta 1, and BMP-2 alone) from a polylactide coating of titanium implants does not lead to ectopic bone formation in sheep muscle. J. Control. Release 95 (2004) 249-256
282. Wilkie D., Bowman B., Lyga A., Bagi C.M., Miller S.C., Ranges G.E., and Carley W. Cerivastatin increases cortical bone formation in OVX rats. J. Bone Miner. Res. 15 Suppl. (2000) s549
283. Winkler D.G., Sutherland M.K., Geoghegan J.C., Yu C., Hayes T., Skonier J.E., Shpektor D., Jonas M., Kovacevich B.R., Staehling-Hampton K., Appleby M., Brunkow M.E., et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 22 (2003) 6267-6276
284. Winkler D.G., Yu C., Geoghegan J.C., Ojala E.W., Skonier J.E., Shpektor D., Sutherland M.K., and Latham J.A. Noggin and sclerostin bone morphogenetic protein antagonists form a mutually inhibitory complex. J. Biol. Chem. 279 (2004) 36293-36298
285. Winkler D.G., Sutherland M.S., Ojala E., Turcott E., Geoghegan J.C., Shpektor D., Skonier J.E., Yu C., and Latham J.A. Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins. J. Biol. Chem. 280 (2005) 2498-2502
286. Wong R.W., and Rabie A.B. Effect of naringin collagen graft on bone formation. Biomaterials 27 (2006) 1824-1831
287. Woo J.T., Kasai S., Stern P.H., and Nagai K. Compactin suppresses bone resorption by inhibiting the fusion of prefusion osteoclasts and disrupting the actin ring in osteoclasts. J. Bone Miner. Res. 15 (2000) 650-662
288. Woo J.T., Nakagawa H., Notoya M., Yonezawa T., Udagawa N., Lee I.S., Ohnishi M., Hagiwara H., and Nagai K. Quercetin suppresses bone resorption by inhibiting the differentiation and activation of osteoclasts. Biol. Pharm. Bull. 27 (2004) 504-509
289. Wood N. The effects of dietary bioflavonoid (rutin, quercetin, and naringin) supplementation on physiological changes in molar crestal alveolar bone-cemento-enamel junction distance in young rats. J. Med. Food 7 (2004) 192-196
290. Wozney J.M. The bone morphogenetic protein family and osteogenesis. Mol. Reprod. Dev. 32 (1992) 160-167
291. Wozney J.M., Rosen V., Celeste A.J., Mitsock L.M., Whitters M.J., Kriz R.W., Hewick R.M., and Wang E.A. Novel regulators of bone formation: Molecular clones and activities. Science 242 (1988) 1528-1534
292. Xu Q., Zhang T., Han Q.D., and Zhang Y.Y. [Binding between alpha 1A-adrenergic receptor and segment of bone morphogenetic protein-1 in human embryonic cell 293]. Sheng Li Xue Bao 55 (2003) 692-698
293. Yamaguchi M., and Jie Z. Effect of polyphenols on calcium content and alkaline phosphatase activity in rat femoral tissues in vitro. Biol. Pharm. Bull. 24 (2001) 1437-1439
294. Yamaguchi M., Ogata N., Shinoda Y., Akune T., Kamekura S., Terauchi Y., Kadowaki T., Hoshi K., Chung U.I., Nakamura K., and Kawaguchi H. Insulin receptor substrate-1 is required for bone anabolic function of parathyroid hormone in mice. Endocrinology 146 6 (2005) 2620-2628
295. Yamaguchi T., Kanatani M., Yamauchi M., Kaji H., Sugishita T., Baylink D.J., Mohan S., Chihara K., and Sugimoto T. Serum levels of insulin-like growth factor (IGF); IGF-binding proteins-3, -4, and -5; and their relationships to bone mineral density and the risk of vertebral fractures in postmenopausal women. Calcif. Tissue Int. 78 (2006) 18-24
296. Yamasaki K., Miura F., and Suda T. Prostaglandin as a mediator of bone resorption induced by experimental tooth movement in rats. J. Dent. Res. 59 (1980) 1635-1642
297. Yamashita M., Ying S.X., Zhang G.M., Li C., Cheng S.Y., Deng C.X., and Zhang Y.E. Ubiquitin ligase Smurf1 controls osteoblast activity and bone homeostasis by targeting MEKK2 for degradation. Cell 121 (2005) 101-113
298. Yamazaki I. Effect of ipriflavone on accessory sexual organs and bone metabolism in male rats. Bone Miner. 2 (1987) 271-280
299. Yamazaki M., Tokui T., Ishigami M., and Sugiyama Y. Tissue-selective uptake of pravastatin in rats: Contribution of a specific carrier-mediated uptake system. Biopharm. Drug Dispos. 17 (1996) 775-789
300. Yang R.S., Liu T.K., and Lin-Shiau S.Y. Increased bone growth by local prostaglandin E2 in rats. Calcif. Tissue Int. 52 (1993) 57-61
301. Yang X., and Karsenty G. ATF4, the osteoblast accumulation of which is determined post-translationally, can induce osteoblast-specific gene expression in non-osteoblastic cells. J. Biol. Chem. 279 (2004) 47109-47114
302. Young P.P., Hofling A.A., and Sands M.S. VEGF increases engraftment of bone marrow-derived endothelial progenitor cells (EPCs) into vasculature of newborn murine recipients. Proc. Natl. Acad. Sci. USA 99 (2002) 11951-11956
303. Yu J.H., Wells H., Moghadam B., and Ryan Jr. W.J. Cyclic AMP formation and release by cultured bone cells stimulated with prostaglandin E2. Prostaglandins 17 (1979) 61-69
304. Yu T.C., and Miller S.J. The hedgehog pathway: Revisited. Dermatol. Surg. 30 (2004) 583-584
305. Zangari M., Esseltine D., Lee C.K., Barlogie B., Elice F., Burns M.J., Kang S.H., Yaccoby S., Najarian K., Richardson P., Sonneveld P., and Tricot G. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br. J. Haematol. 131 (2005) 71-73
306. Zerath E., Holy X., Noel B., Malouvier A., Hott M., and Marie P.J. Effects of BMP-2 on osteoblastic cells and on skeletal growth and bone formation in unloaded rats. Growth Horm. IGF Res. 8 (1998) 141-149
307. Zhang J.P., Wu T.M., Hu Z.L., and Qian D.H. Inhibitory effect of quercetin on tumor necrosis factor and interleukin-1 beta pro-osteoclastic activities. Zhongguo Yao Li Xue Bao 17 (1996) 261-263
308. Zhang T., Xu Q., Chen F.R., Han Q.D., and Zhang Y.Y. Yeast two-hybrid screening for proteins that interact with alpha1-adrenergic receptors. Acta Pharmacol. Sin. 25 (2004) 1471-1478
309. Zhang W.V., and Stott N.S. BMP-2-modulated chondrogenic differentiation in vitro involves down-regulation of membrane-bound beta-catenin. Cell Commun. Adhes. 11 (2004) 89-102
310. Zhang Y., Chang C., Gehling D.J., Hemmati-Brivanlou A., and Derynck R. Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase. Proc. Natl. Acad. Sci. USA 98 (2001) 974-979
311. Zhao M., Qiao M., Oyajobi B.O., Mundy G.R., and Chen D. E3 ubiquitin ligase Smurf1 mediates core-binding factor alpha1/Runx2 degradation and plays a specific role in osteoblast differentiation. J. Biol. Chem. 278 (2003) 27939-27944
312. Ziegler K., Blumrich M., and Hummelsiep S. The transporter for the HMG-CoA reductase inhibitor pravastatin is not present in Hep G2 cells. Evidence for the nonidentity of the carrier for pravastatin and certain transport systems for BSP. Biochim. Biophys. Acta 1223 (1994) 195-201